curasan AG

euro adhoc: Capital measures
curasan AG: increase in capital against cash

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Kleinostheim, March 1, 2007 - Today, curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard, has placed 525,000 new ordinary shares, in the form of bearer shares, as a capital increase against cash. This capital increase was submitted to the Supervisory Board February 28 for approval and authorization on March 1. The capital increase of EUR 525,000, from currently EUR 6,250,000 to EUR 6,775,000, was executed within the framework of existing Authorised Capital (so-called "Genehmigtes Kapital").

The shares offered in this private placement round were subscribed by institutional investors. The subscription right of shareholders does not apply. The issue price of the new shares is EUR 2.41 per share. The new shares have a dividend right, effective January 1, 2007.

The proceeds from this offering will primarily be used for financing a complementary product line of biological materials.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company’s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan’s corporate website at

@@start.t2@@end of announcement                                                 euro adhoc 01.03.2007 19:27:24

ots Originaltext: curasan AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Erwin Amashaufer, Tel. +49 6027/46 86-465, email:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Weitere Meldungen: curasan AG

Das könnte Sie auch interessieren: